Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Leases (2019 - 2023)

Historic Leases for Spyre Therapeutics (SYRE) over the last 5 years, with Q2 2023 value amounting to $2.3 million.

  • Spyre Therapeutics' Leases fell 3593.36% to $2.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.3 million, marking a year-over-year decrease of 3593.36%. This contributed to the annual value of $3.4 million for FY2022, which is 987.91% down from last year.
  • As of Q2 2023, Spyre Therapeutics' Leases stood at $2.3 million, which was down 3593.36% from $3.3 million recorded in Q1 2023.
  • Over the past 5 years, Spyre Therapeutics' Leases peaked at $5.0 million during Q2 2019, and registered a low of $621000.0 during Q1 2019.
  • Its 5-year average for Leases is $3.8 million, with a median of $4.0 million in 2021.
  • In the last 5 years, Spyre Therapeutics' Leases soared by 65877.62% in 2020 and then plummeted by 3593.36% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Leases (Quarter) stood at $4.7 million in 2019, then fell by 10.5% to $4.2 million in 2020, then dropped by 10.02% to $3.8 million in 2021, then decreased by 9.88% to $3.4 million in 2022, then tumbled by 32.48% to $2.3 million in 2023.
  • Its Leases stands at $2.3 million for Q2 2023, versus $3.3 million for Q1 2023 and $3.4 million for Q4 2022.